This research delved into the development of novel potential cancer drugs targeting class 1 histone deacetylases (HDACs) and highlights the promise of two specific ligands, LIG1 and LIG2, as potent HDAC inhibitors with potential applications in cervical cancer treatment. This evidence concerns the gene HDAC9 and cancer.